central and peripheral glp-1 systems independently suppress eating the Degenerating Brain: Exploring Mechanistic Insights and Therapeutic Potential Beyond Weight Loss: GLP-1 Usage

Finally, the study explored whether granulocyte-colony stimulating factor (G-CSF) could enhance the protective effects of AcSDKP

These data support the impaired fasting glucose and enhanced insulin secretion previously demonstrated in vitiligo patients (Karadag et al., 2011)

The LEADER trial demonstrated that liraglutide reduced the risk of cardiovascular death by 22%, cut death from any cause by 15%, and reduced major adverse cardiovascular events (heart attack, stroke, or cardiovascular death) by 13%

The Endocrine Society presented data at ENDO 2025 showing that women and older adults on semaglutide face the highest risk of muscle loss, but that higher protein intake significantly reduced this risk

The journey from preclinical promise to clinical application requires careful consideration

Currently available therapies are useful only for symptomatic control and tend to lose efficacy as time progresses